| 166.15 -2.89 (-1.71%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 197.97 | 1-year : | 231.22 |
| Resists | First : | 169.49 | Second : | 197.97 |
| Pivot price | 157.85  |
|||
| Supports | First : | 144.46 | Second : | 129 |
| MAs | MA(5) : | 167.04 |
MA(20) : | 152.69 |
| MA(100) : | 131.31 |
MA(250) : | 138.99 |
|
| MACD | MACD : | 7.6 |
Signal : | 6.5 |
| %K %D | K(14,3) : | 94.4 |
D(3) : | 95.8 |
| RSI | RSI(14): 66.7 |
|||
| 52-week | High : | 175.77 | Low : | 100.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RGEN ] has closed below upper band by 29.2%. Bollinger Bands are 66.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 168.28 - 169.13 | 169.13 - 169.82 |
| Low: | 162.89 - 163.79 | 163.79 - 164.53 |
| Close: | 164.83 - 166.24 | 166.24 - 167.4 |
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Tue, 18 Aug 2026
The Bull Case For Repligen (RGEN) Could Change Following Raised Guidance On Q2 Outperformance - Learn Why - simplywall.st
Mon, 17 Aug 2026
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks - StockStory
Sun, 16 Aug 2026
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN - MarketBeat
Sat, 15 Aug 2026
Repligen (RGEN) Stock Forum and Discussion - Moomoo
Fri, 14 Aug 2026
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A - stocktitan.net
Mon, 10 Aug 2026
Repligen Corporation (RGEN) Stock Analysis: A Healthcare Standout with 13.3% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 56 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 119.9 (%) |
| Shares Short | 5,810 (K) |
| Shares Short P.Month | 5,730 (K) |
| EPS | 0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.43 |
| Profit Margin | 5.2 % |
| Operating Margin | 9.3 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | 1.9 % |
| Qtrly Rev. Growth | 11.8 % |
| Gross Profit (p.s.) | 7.48 |
| Sales Per Share | 13.91 |
| EBITDA (p.s.) | 2.55 |
| Qtrly Earnings Growth | -66 % |
| Operating Cash Flow | 135 (M) |
| Levered Free Cash Flow | 113 (M) |
| PE Ratio | 224.52 |
| PEG Ratio | 2.1 |
| Price to Book value | 4.43 |
| Price to Sales | 11.94 |
| Price to Cash Flow | 69.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|